A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next ten years and challenge the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies and as drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the sales of current market leaders. Targeted synthetic DMARDs, particularly JAK inhibitors, will fulfill the need for orally dosed therapies and increasingly capture early-line patient share.
Geographies: United States, EU5, Japan.
Primary research: 24 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other DRG research.
Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2029, segmented by brands / biosimilars.
Emerging therapies: Phase III/PR: 5 drugs; Phase II: 2 drugs.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.